UFF
EDIT icon

USA Financial Formulas’s Editas Medicine EDIT Stock Holding History

USA Financial Formulas’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,675
Closed -$382K – 337
2018
Q3 		$382K Buy
+10,675
New +$345K 0.1% 163

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

USA Financial Formulas's EDIT Position: Q4 2018 in Review

USA Financial Formulas sold out of Editas Medicine (EDIT) in Q4 2018, closing a stake of 10,675 shares — an estimated $382K sold.

USA Financial Formulas first reported a position in EDIT in Q3 2018 and held it in 1 quarter. The position peaked at $382K in Q3 2018. 194 funds tracked by Wall St. Rank hold EDIT as of Q4 2018.

  • USA Financial Formulas reported no remaining Editas Medicine position as of Q4 2018 after selling out during the quarter.
  • USA Financial Formulas sold 10,675 Editas Medicine shares in Q4 2018, an estimated $382K.
  • USA Financial Formulas first reported a position in Editas Medicine in Q3 2018 and held it in 1 quarter.
  • USA Financial Formulas's Editas Medicine position peaked at $382K in Q3 2018.
  • 194 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2018.

Based on USA Financial Formulas's 13F filing for Q4 2018, filed 14 Feb 2019.